Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial
Qin Y, Zhou Y, Chen SH, Zhao XL, Ran L, Zeng XL, Wu Y, Chen JL, Kang C, Shu FR, Zhang QY, Mi MT
PloS one · 79 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Subvenciones
- National Natural Science Foundation of China (30972469); National Natural Science Foundation of China (81273059)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2015-07-30 · PLoS One · vol. 10 · número 7 · pág. e0133496
- Editorial
- Public Library of Science
- Citado
- 101 citas · más que el 98% de estudios similares · 8.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Aquaculture Nutrition and Growth
- Palabras clave
- fish oil supplementation, non-alcoholic fatty liver disease, hyperlipidemia, serum lipids, glucose, insulin, FGF21, prostaglandin E2, eicosapentaenoic acid, docosahexaenoic acid, adiponectin, TNF-α, leukotriene B4, alanine aminotransferase, gamma-glutamyl transferase, corn oil, omega-3 fatty acids
- MeSH
- humans, insulin, glucose, blood glucose, lipids, docosahexaenoic acids, eicosapentaenoic acid, dinoprostone, fish oils, fibroblast growth factors, liver function tests, kidney function tests, double-blind method, dietary supplements, adult, middle aged, female, male, hyperlipidemias, non-alcoholic fatty liver disease
12 autores
- Yu Qin🇨🇳Army Medical University
- Yong Gui Zhou🇨🇳Army Medical University
- Shihui Chen🇨🇳Army Medical University
- Xiao-Lan Zhao🇨🇳Army Medical University; Southwest Hospital
- Li Ran🇨🇳Army Medical University
- Xiang-Long Zeng🇨🇳Army Medical University
- Ying Wu🇨🇳Army Medical University
- Junli Chen🇨🇳Army Medical University
- Chao Kang🇨🇳Army Medical University
- Furong Shu🇨🇳Army Medical University
- Qianyong Zhang🇨🇳 · autor de correspondenciaArmy Medical University
- Mantian Mi🇨🇳 · autor de correspondenciaArmy Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Unlabelled
Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with NAFLD associated with hyperlipidemia were randomly assigned to consume fish oil (n=40, 4 g/d) or corn oil capsules (n=40, 4 g/d) for 3 months in a double-blind, randomized clinical trial. Blood levels of lipids, glucose and insulin, liver enzymes, kidney parameters and cytokines at baseline and the end of the study were measured. Seventy people finished the trial. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid significantly increased in the fish oil group after intervention. After adjustment for age, gender and BMI, fish oil significantly decreased fasting serum concentrations of total cholesterol, triglyceride, apolipoprotein B and glucose (by (mean±SD) 0.49±0.43 mmol/L, 0.58±0.89 mmol/L, 0.28±0.33 g/L and 0.76±0.56 mmol/L, respectively, P<0.05), as well as alanine aminotransferase and γ-glutamyl transpeptidase levels (by (median (interquartile)) 9.0(0.5, 21.5) and 7.0(2.2, 20.0) IU/L, respectively, P<0.05), significantly increased serum adiponectin levels (by 1.29±0.62 μg/mL, P<0.001), and reduced serum levels of tumor necrosis factor α, leukotrienes B4, fibroblast growth factor 21 (FGF21), cytokeratin 18 fragment M30 and prostaglandin E2 (by 1.70±1.18 pg/mL, 0.59±0.28 ng/mL, 121±31 pg/mL, 83±60 IU/L and 10.9±2.3 pg/mL, respectively, P<0.001). Corn oil had no effect except for increasing serum creatinine concentrations by 7.7±8.9 μmol/L (P=0.008). The effects of fish oil on lipids, glucose and γ-glutamyl transpeptidase were positively correlated with the reductions of serum FGF21 and prostaglandin E2 concentrations after adjustment for age, gender and BMI (r = 0.275 to 0.360 and 0.261 to 0.375, respectively, P<0.05). In conclusion, our findings suggest that fish oil can benefit metabolic abnormalities associated with NAFLD treatment.
Trial registration
ChiCTR-TRC-12002380.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.